NewAmsterdam COO Exits Without Named Successor at EU Launch Eve

NewAmsterdam Pharma is a Netherlands-domiciled, Nasdaq-listed biopharma focused on obicetrapib, an oral once-daily CETP inhibitor designed to lower LDL-C in patients inadequately treated by statins. Its commercialization model in Europe is built around a license with the Menarini Group, which holds exclusive regional rights and is responsible for regulatory interactions and launches. NewAmsterdam is entitled to tiered royalties ranging from low double-digits to mid-twenties on European net sales, plus up to €833 million in milestone payments.

The company received its most significant regulatory event to date on July 24, 2026, when the EMA's Committee for Medicinal Products for Human Use issued a positive opinion recommending authorization for Ubeslo® (obicetrapib monotherapy) and Evlarco® (obicetrapib plus ezetimibe fixed-dose combination). A European Commission decision is expected later in 2026, and Menarini is targeting product launches in Germany and the United Kingdom in the fourth quarter of 2026. In parallel, the pivotal PREVAIL cardiovascular outcomes trial — which enrolled over 9,500 patients — has a planned interim analysis in Q4 2026, with results expected in Q1 2027.

Financially, NewAmsterdam reported $678.3 million in cash, cash equivalents, and marketable securities as of June 30, 2026, down from $728.9 million at year-end 2025. Management has stated that the cash position is sufficient to fund operations through the PREVAIL readout and a subsequent U.S. commercial launch if approved. Revenue is predominantly derived from the Menarini supply agreement and has run at roughly $3–4 million per quarter in 2026, while quarterly net losses have ranged from approximately $48 million to $64 million.